Ravi Mehrotra analyst

Currently out of the existing stock ratings of Ravi Mehrotra, 14 are a BUY (100%).

Ravi Mehrotra

Work Performance Price Targets & Ratings Chart

Analyst Ravi Mehrotra, currently employed carries an average stock price target met ratio of 95% that have a potential upside of 28.49% achieved within 300 days.

Ravi Mehrotra’s has documented 27 price targets and ratings displayed on 2 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on BIIB, Biogen at 19-Mar-2015.

Wall Street Analyst Ravi Mehrotra

Analyst best performing recommendations are on BIIB (BIOGEN).
The best stock recommendation documented was for BIIB (BIOGEN) at 3/4/2013. The price target of $200 was fulfilled within 56 days with a profit of $43.45 (27.75%) receiving and performance score of 4.96.

Average potential price target upside

BIIB Biogen CELG Celgene

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

313

$82.94 (36.05%)

325

7 days ago

32/45 (71.11%)

$82.94 (36.05%)

418

Buy

294

$63.94 (27.79%)

294

21 days ago

7/24 (29.17%)

$62.18 (26.82%)

255

Buy

317

$86.94 (37.79%)

317

23 days ago

39/59 (66.1%)

$92.54 (41.23%)

149

Buy

300

$69.94 (30.40%)

325

1 months 26 days ago

9/18 (50%)

$81.94 (37.58%)

260

Buy

340

$109.94 (47.79%)

340

2 months 3 days ago

17/35 (48.57%)

$109.96 (47.80%)

342

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Ravi Mehrotra?

On 2012

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?